Cholestatic liver injury after glimepiride therapy.
Drug induced hepatotoxicity has been reported infrequently with sulfonylureas. For glimepiride, a second-generation sulfonylurea there is no report of hepatotoxicity in English literature. A patient with non-insulin-dependent diabetes mellitus who developed cholestatic liver injury soon after initiation of glimepiride therapy is presented. Complete work-up disclosed no other cause for hepatotoxicity including negative serological results for viral hepatitis. Liver biopsy was consistent with drug-induced cholestasis. The patient recovered 50 days after stopping glimepiride with no further recurrences.
Chounta
Athina
A
Hepatology Division, 4th Academic Department of Internal Medicine, Attikon University General Hospital, 7 Orfeos Street, Palaio Faliro, 17564 Athens, Greece. hgiama@ath.forthnet.gr
Zouridakis
Spyros
S
Ellinas
Christos
C
Tsiodras
Sotirios
S
Zoumpouli
Christina
C
Kopanakis
Stylianos
S
Giamarellou
Helen
H
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D002779:Cholestasis / Q000139:chemically induced* / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D009336:Necrosis; D013453:Sulfonylurea Compounds / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride